These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
565 related articles for article (PubMed ID: 24965788)
1. Adrenocorticotropic hormone versus prednisolone in the treatment of infantile spasms post vigabatrin failure. Jones K; Snead OC; Boyd J; Go C J Child Neurol; 2015 Apr; 30(5):595-600. PubMed ID: 24965788 [TBL] [Abstract][Full Text] [Related]
3. Very-High-Dose Prednisolone Before ACTH for Treatment of Infantile Spasms: Evaluation of a Standardized Protocol. Eliyan Y; Heesch J; Alayari A; Rajaraman RR; Sankar R; Hussain SA Pediatr Neurol; 2019 Oct; 99():16-22. PubMed ID: 31331669 [TBL] [Abstract][Full Text] [Related]
4. Infantile Spasms-Have We Made Progress? Kelley SA; Knupp KG Curr Neurol Neurosci Rep; 2018 Apr; 18(5):27. PubMed ID: 29671077 [TBL] [Abstract][Full Text] [Related]
5. Vigabatrin as First-Line Treatment for Infantile Spasms Not Related to Tuberous Sclerosis Complex. Jones K; Go C; Boyd J; Ochi A; McCoy B; Puka K; Snead OC Pediatr Neurol; 2015 Aug; 53(2):141-5. PubMed ID: 26227562 [TBL] [Abstract][Full Text] [Related]
6. Randomized, Single-Blind, Parallel Clinical Trial on Efficacy of Oral Prednisolone Versus Intramuscular Corticotropin on Immediate and Continued Spasm Control in West Syndrome. Wanigasinghe J; Arambepola C; Sri Ranganathan S; Sumanasena S; Attanapola G Pediatr Neurol; 2015 Sep; 53(3):193-9. PubMed ID: 26216500 [TBL] [Abstract][Full Text] [Related]
7. Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Go CY; Mackay MT; Weiss SK; Stephens D; Adams-Webber T; Ashwal S; Snead OC; ; Neurology; 2012 Jun; 78(24):1974-80. PubMed ID: 22689735 [TBL] [Abstract][Full Text] [Related]
8. Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society. Mackay MT; Weiss SK; Adams-Webber T; Ashwal S; Stephens D; Ballaban-Gill K; Baram TZ; Duchowny M; Hirtz D; Pellock JM; Shields WD; Shinnar S; Wyllie E; Snead OC; ; Neurology; 2004 May; 62(10):1668-81. PubMed ID: 15159460 [TBL] [Abstract][Full Text] [Related]
9. Compliance With Standard Therapies and Remission Rates After Implementation of an Infantile Spasms Management Guideline. Mytinger JR; Albert DVF; Twanow JD; Vidaurre J; Tan Y; Brock GN; Ostendorf AP Pediatr Neurol; 2020 Mar; 104():23-29. PubMed ID: 31911027 [TBL] [Abstract][Full Text] [Related]
10. Vigabatrin with hormonal treatment versus hormonal treatment alone (ICISS) for infantile spasms: 18-month outcomes of an open-label, randomised controlled trial. O'Callaghan FJK; Edwards SW; Alber FD; Cortina Borja M; Hancock E; Johnson AL; Kennedy CR; Likeman M; Lux AL; Mackay MT; Mallick AA; Newton RW; Nolan M; Pressler R; Rating D; Schmitt B; Verity CM; Osborne JP; Lancet Child Adolesc Health; 2018 Oct; 2(10):715-725. PubMed ID: 30236380 [TBL] [Abstract][Full Text] [Related]
11. Topiramate and adrenocorticotropic hormone (ACTH) as initial treatment for infantile spasms. Peltzer B; Alonso WD; Porter BE J Child Neurol; 2009 Apr; 24(4):400-5. PubMed ID: 19225138 [TBL] [Abstract][Full Text] [Related]
12. Adrenocorticotropic hormone for the treatment of West Syndrome in children. Shumiloff NA; Lam WM; Manasco KB Ann Pharmacother; 2013 May; 47(5):744-54. PubMed ID: 23606552 [TBL] [Abstract][Full Text] [Related]
13. Fulminant vigabatrin toxicity during combination therapy with adrenocorticotropic hormone for infantile spasms: Three cases and review of the literature. Bhalla S; Skjei K Epilepsia; 2020 Oct; 61(10):e159-e164. PubMed ID: 32944947 [TBL] [Abstract][Full Text] [Related]
15. A risk-benefit assessment of treatments for infantile spasms. Nabbout R Drug Saf; 2001; 24(11):813-28. PubMed ID: 11665869 [TBL] [Abstract][Full Text] [Related]
16. The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial. Lux AL; Edwards SW; Hancock E; Johnson AL; Kennedy CR; Newton RW; O'Callaghan FJ; Verity CM; Osborne JP Lancet; 2004 Nov 13-19; 364(9447):1773-8. PubMed ID: 15541450 [TBL] [Abstract][Full Text] [Related]